The Food and Drug Administration (FDA) has authorized the emergency use of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients, and the Centers for Medicare & Medicaid Services (CMS) has created new billing codes for the treatment.
The emergency use authorization covers treatment of symptoms in patients when they have a positive COVID-19 test result, are at high-risk for progression to severe COVID-19, and alternative COVID-19 treatment options approved or authorized by the FDA aren’t accessible or clinically appropriate for them.
The new CMS billing codes for bebtelovimab include:
- Q0222
- Long descriptor: Injection, bebtelovimab, 175 mg
- Short descriptor: Bebtelovimab 175
- M0222
- Long Descriptor: Intravenous injection, bebtelovimab, includes injection and post administration monitoring
- Short Descriptor: Bebtelovimab injection
- M0223
- Long Descriptor: Intravenous injection, bebtelovimab — includes injection and post-administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
- Short Descriptor: Bebtelovimab injection home
Additional information is available on the CMS COVID-19 Monoclonal Antibodies web page.